Cite
HARVARD Citation
Chan, A. et al. (n.d.). P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab. Journal for immunotherapy of cancer. p. A10. [Online].